in 25 days Kaiser Permanente — Kaiser Northwest's Zepbound criteria move to the rev 10/08/2026 document — cite that version in an appeal from this date See the changelog
WalletNoise

Aetna (CVS Health)

Insurer (Caremark-administered) · updated October 13, 2026

Coverage right now

Criteria are essentially identical to the Caremark template (same BMI wording, 6-month program requirement, 5% reauth gate, same quantity limits). The difference is formulary architecture: standard Aetna commercial formularies made Zepbound exception-only after July 2025 with a step through Wegovy, while FE-compatible plans kept it PA-covered. Many Aetna plans exclude weight-loss drugs entirely (CPB 0039).

Drug status

DrugStatusDetailConfidence
Wegovy® (semaglutide injection)Preferred
from Jul 1, 2025
Preferred GLP-1 with PA on standard commercial formularies since 7/1/2025. sourcehigh
Zepbound® (tirzepatide)Exception only
from Jul 1, 2025 to Sep 30, 2026
Non-formulary on standard commercial formularies (ACCF/ACF/ACFC/SCCF/SF/SFC/VF/VFC). Policy 6981-A is an alternatives notice, not a route back to Zepbound: it names Wegovy the primary formulary alternative and Mounjaro the secondary, and the only authorization it grants after documented inadequate response, intolerance or contraindication to Wegovy is for Mounjaro. The 2.5, 5, 7.5 and 10 mg single-dose vials sit outside the policy entirely — it excludes them by strength as covered under the LillyDirect manufacturer program. Covered with PA on FE-compatible plans. Returns as additional preferred template option 10/1/2026. sourcehigh
Zepbound® (tirzepatide)Preferred
from Oct 1, 2026
Returns as additional preferred option on Caremark-administered templates. Aetna's own formulary update for the same date lists ZEPBOUND under Formulary Additions for the Aetna Standard Plan (individuals and families), so the return is now carried by an Aetna-published document and not only by the administrator's press release. cvshealth.com· aetna.comhigh
Wegovy® tablets (oral semaglutide)Preferred
from Jan 5, 2026
Same preferred status as injectable on Caremark template formularies; Aetna-specific policy document not located. sourcemedium
Foundayo™ (orforglipron)Covered
from Jun 1, 2026 to Sep 30, 2026
New-to-market block removed on Caremark template 6/1/2026 where plans cover weight loss; Aetna tier placement not yet published. sourcemedium
Foundayo™ (orforglipron)Preferred
from Oct 1, 2026
Aetna's own formulary update for October 1, 2026 lists FOUNDAYO under Endocrine and Metabolic, Antiobesity in its "Tier Changes: Non-Preferred to Preferred" table, which also tells you its placement before that date was non-preferred rather than the unplaced reading this file had to settle for. Scope: the update is published for the Aetna Standard Plan (individuals and families), so a Caremark-administered employer template may tier it differently and the plan booklet still decides whether a weight-loss benefit exists at all. sourcehigh

What these rules come to in dollars — every dose, priced under this coverage:

What preferred, covered and exception only mean
Preferred
On the formulary at the plan's best tier for this class. Usually still needs prior authorization — preferred is not the same as automatic.
Covered
On the formulary, but not the plan's first choice for this class. Often a higher copay tier than a preferred drug.
Non preferred
On the formulary at a disadvantaged tier, or reachable only after trying a preferred drug first.
Exception only
Not routinely covered. Obtainable only through a formulary-exception request that meets the plan's published criteria.
Excluded
Not on the formulary at all. A benefit exclusion is a different fight from a PA denial and is appealed differently.
Varies
The payer's own documents differ by plan or line of business, so a single answer here would be wrong.
Unknown
Not yet verified against a primary document. Recorded as absent rather than guessed.
N/A
Not applicable to this payer.

Prior authorization criteria

high
PA required
Yes where the plan includes a weight-loss benefit. CPB 0039: many Aetna benefit plans specifically exclude coverage of weight reduction medications — check the plan booklet before anything else.
Initial BMI
BMI >= 30, OR BMI >= 27 with >= 1 weight-related comorbidity. Wegovy adolescents 12-17: BMI >= 95th percentile. The Zepbound sleep-apnea route is gated differently and only reachable on FE-compatible plans: bulletin 6947-C asks for an adult with obesity plus an established diagnosis of moderate to severe OSA at an apnea-hypopnea index of at least 15 events per hour on polysomnography or a technically adequate home sleep apnea test, and states no separate BMI number. The standard-plan bulletin 6192-C carries no OSA indication at all, so on a standard plan that route does not exist.
Comorbidities
At least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia).
Lifestyle requirement
Comprehensive weight management program (behavioral modification, reduced-calorie diet, increased physical activity, continuing follow-up) for >= 6 months prior to drug therapy. Aetna applies it to the sleep-apnea route as well, which is worth knowing because some payers drop the retrospective trial on their non-weight indications and Aetna does not.
Initial authorization
Wegovy 7. Zepbound 8 for weight reduction and 6 for obstructive sleep apnea, both read off Aetna's own Zepbound bulletins rather than inferred from the Caremark template. Continuation is 12 months on every route and every drug here.
Reauthorization
Lost at least 5% of baseline body weight OR maintained the initial 5% loss. Pediatric: BMI reduction from baseline.
Step therapy
Structural rather than in-policy, and scoped to the exclusion: THROUGH SEPTEMBER 30, 2026, a Zepbound request on a standard formulary was answered by exception policy 6981-A, which offered Wegovy first and, on documented inadequate response, intolerance or contraindication to Wegovy, approved Mounjaro rather than Zepbound. Zepbound returns as an additional preferred option on Caremark-administered templates on October 1, 2026. Aetna has published no criteria document dated to that return, but it does publish two Zepbound PA-with-Limit bulletins and both were read in full on 2026-10-13: 6192-C P08-2024_R for standard plans and 6947-C P04-2025 for FE-compatible ones. Neither contains a step through Wegovy -- they go straight to the weight-management criteria -- so the Wegovy-first step was a property of the exclusion, not of Zepbound. What remains undocumented is which bulletin a given plan applies from October 1, so ask in writing rather than assuming either the old exception route or none. Re-checked on 2026-10-04, after the return: 6981-A is still posted unchanged, still numbered P04-2025, and still names Wegovy primary and Mounjaro secondary. Expect it to be quoted at you anyway, and ask which document the plan is actually applying.
Quantity limits
Wegovy 0.25-1 mg: 2 mL/21 days and 6 mL/63 days; 1.7/2.4 mg: 3 mL/21 days and 9 mL/63 days. One carton of 4 pens per 28 days either way -- the mL figures differ only because the higher strengths come in 0.75 mL pens. Zepbound, every strength: 2 mL/21 days and 6 mL/63 days, which 6192-C states as 1 package of 4 pens OR 4 single-dose vials per 21 days, and 3 packages or 12 vials per 63 days. The 21- and 63-day windows are deliberate: Aetna says it uses them for 28- and 84-day fills to leave room for refill processing.

Primary criteria document: aetna.com· aetna.com· aetna.com

Exceptions and appeals

Appeal deadline
180 days
Deadline detail
180 days internal; external review ~4 months after final adverse determination.
Exception route
ePA via CoverMyMeds/Surescripts or fax through CVS Caremark PA. Aetna Pharmacy line 1-888-792-3862. Formulary exception per policy 6981-A documentation requirements.
Turnaround
Standard PA ~3-5 business days; expedited 24-72 hours (secondary source).
Where
Per your denial letter (plan-specific).

Source: findhonestcare.com

Dated changes

  • Jul 1, 2025 Zepbound off standard template; Wegovy sole preferred (CVS reported >95% of members transitioned) source
  • Mar 10, 2026 CPB 0039 (Weight Reduction) re-reviewed source
  • Oct 1, 2026 Zepbound back as additional preferred on templates source
  • Oct 1, 2026 Foundayo moves non-preferred -> preferred, and Zepbound is added to the formulary, both named in Aetna's own Standard Plan formulary update (GR-69746-4) rather than only in the CVS press release source
Aetna Medicaid (Aetna Better Health) runs separate state-specific criteria. For a denial dated on or before September 30, 2026, the Wegovy-first step was the crux: document intolerance or inadequate response to Wegovy specifically — and note that what 6981-A then approved was Mounjaro, not Zepbound. That advice expires with the exclusion. From October 1, 2026 Zepbound is an additional preferred option on Caremark-administered templates. Aetna publishes no criteria document dated to the return, but it does publish Zepbound criteria: prepare against 6192-C on a standard plan and 6947-C on an FE-compatible one, and ask the plan in writing which of the two it is applying, because that answer decides whether the sleep-apnea route is open to you at all. On the wegovy-oral citation: managedhealthcareexecutive.com began serving this environment a Cloudflare challenge on 2026-09-11 and refused curl, WebFetch and a real browser alike, so that row's source cannot be opened here and its claim has only been re-confirmed through host-scoped search. It is trade press behind an already-MEDIUM row, and every Aetna-published document this file cites was read in full on that date.
These are each payer's standard template. Employer plans customize them, so the same PBM can cover a drug for one employer and exclude it for another — a status here is a starting point, not your plan. A benefit exclusion is also a different fight from a PA denial. Always request your own plan's criteria in writing; you are entitled to them.